進行した肝細胞癌患者におけるガルニセルトリブ（TGF-β1受容体タイプI阻害剤）とソラフェニブの第2相試験

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma2019 · 143 citations
2. 2Laminin-5 With Transforming Growth Factor-β1 Induces Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma2005 · 249 citations
3. 3New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,540 citations
4. 4A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).2018 · 30 citations
5. 5TRANSFORMING GROWTH FACTOR β1 AND SOLUBLE FAS SERUM LEVELS IN HEPATOCELLULAR CARCINOMA2000 · 47 citations